ArticlePharmacoEconomics2004
The burden of migraine in Spain: beyond direct costs.
Article in PharmacoEconomics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Cost of disorders of the brain in Spain.PloS one · 2014Pooled it
- Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.PharmacoEconomics · 2005Pooled it
- Study protocol for a pragmatic randomised controlled trial in general practice investigating the effectiveness of acupuncture against migraine.BMC complementary and alternative medicine · 2008Trial
- Economic burden of blindness and moderate to severe vision impairment in Slovenia.Health economics review · 2026Article
- Trends in Acupuncture Therapy for Microcirculation and Hemorheology from 1998 to 2023: A Bibliometric and Visualized Study.Journal of pain research · 2024Article
- Prevalence of Migraine in General Spanish Population; Factors Related and Use of Health Resources.International journal of environmental research and public health · 2021Article
- Productivity Losses Due to Migraine in Slovenia: An Analysis of Absenteeism and Presenteeism Costs Based on Administrative and Self-Reported Data.Zdravstveno varstvo · 2020Article
- Observational
- Transforming pain medicine: adapting to science and society.European journal of pain (London, England) · 2013Review
- Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).The journal of headache and pain · 2012Article
- New uses of the Migraine Screen Questionnaire (MS-Q): validation in the Primary Care setting and ability to detect hidden migraine. MS-Q in Primary Care.BMC neurology · 2010Article
- Impact of headache in Europe: a review for the Eurolight project.The journal of headache and pain · 2008Review
- Topiramate: the evidence for its therapeutic value in the prevention of migraine.Core evidence · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the economic burden of migraine in Spain, from the societal perspective.
methodsThe Spanish 2001 annual direct (pharmacy, primary care, specialist and emergency room visits) and indirect (missed workdays and reduced work performance) costs were calculated using the prevalence approach. The human-capital method was used to calculate indirect costs. The sources used were published epidemiological and resource use studies using the International Headache Society diagnostic criteria from official and unofficial databases.
resultsThe Spanish population with migraine was estimated to be 3,617,600 patients, 92.5% being of a working age. The economic burden of migraine was about euro 1076 million. The direct costs represented only 32.0% of the total burden (euro 344 million), 39.2% being for primary care visits, 28.7% for specialist visits, 20.5% for emergency room visits and a further 11.7% for migraine-specific prescription drugs (serotonin 5-HT(1B/1D) receptor agonists [triptans] 10.8%, ergots 0.9%). The indirect cost was estimated at euro 732 million annually, representing euro 453.55 per working patient with migraine.
conclusionsAs in many other developed countries, migraine represents a considerable economic burden in Spain, especially in terms of productivity losses. Therefore, activities should be specifically directed at reducing the indirect costs, and effective treatments, which significantly reduce productivity losses, should be publicly promoted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.